NAV-005 / Navrogen - LARVOL DELTA

[VIRTUAL] Development of NAV-005, a humoral immuno-suppressor antagonist for the treatment of CA125-expressing cancers (AACR 2021) - "We have engineered a human IgG1 Fc fusion protein, called NAV-005, that binds to CA125 with high affinity and blocks its binding to SIGLEC receptors and affected antibodies, thus enabling efficient humoral immune mediated tumor cell killing. NAV-005 is being developed as a novel therapeutic agent to treat humoral immuno-suppressed CA125 expressing cancers."

Oncology • MUC16